IN THE CLAIMS

Amend the claims as follows.

Claims 1-20 (Canceled).

21. (new) A polypeptide consisting essentially of a sequence corresponding to residues 163 to 199 of DP-1, said sequence being:

KNIRRRVYDALNVLMAMNIISKEKKEIKWIGLPTNSA (SEQ ID NO:1).

22. (new) A polypeptide fragment of the polypeptide consisting essentially of the sequence:

KNIRRRVYDALNVLMAMNIISKEKKEIKWIGLPTNSA (SEQ ID NO:1),

which fragment is capable of antagonising the heterodimerisation of a DP protein with an E2F protein.

23. (new) A polypeptide fragment according to claim 22 which comprises the sequence NVLMAMNII (SEQ ID NO:2) or ALNVLMA (SEQ ID NO:7).

24. (new) A polypeptide fragment according to claim 23 which is selected from the group consisting of:

RRRVYDALNVLMAMNIISK (SEQ ID NO:3);
NVLMAMNIISKEKKEIKWIG (SEQ ID NO:4);
RVYDALNVLMAMNIIS (SEQ ID NO:5); and
YDALNVLMAMNIISKEKKEIKWIGLPTNSA (SEQ ID NO:6).

25. (new) A variant of a polypeptide consisting essentially of a sequence corresponding to residues 163 to 199 of DP-1, said sequence being:

KNIRRRVYDALNVLMAMNIISKEKKEIKWIGLPTNSA (SEQ ID NO:1),

said variant differing from the polypeptide by the presence of from 1 to 5 amino acid substitutions in the sequence of said polypeptide, said variant being capable of antagonising the heterodimerisation of a DP protein with an E2F protein.

26. (new) A variant according to claim 25 wherein the substitutions include substitutions selected from one or more residues corresponding to residues 167, 169, 171 and 175 of DP-1.

27. (new) A polypeptide which comprises:
(i) a first portion having an amino acid sequence selected from the group consisting of:

KNIRRRVYDALNVLMAMNIISKEKKEIKWIGLPTNSA (SEQ ID NO:1),
NVLMAMNII (SEQ ID NO:2),
RRRVYDALNVLMAMNIISK (SEQ ID NO:3),
NVLMAMNIISKEKKEIKWIG (SEQ ID NO:4),
RVYDALNVLMAMNIIS (SEQ ID NO:5),
YDALNVLMAMNIISKEKKEIKWIGLPTNSA (SEQ ID NO:6), and
ALNVLMA (SEQ ID NO:7); and

(ii) a second portion, attached to the N- or C-terminus of the first portion, which comprises a sequence of amino acids not naturally contiguous to the first portion in DP-1.

28. (new) A polypeptide according to claim 27 wherein the second portion is a membrane translocation sequence.

29. (new) A polypeptide according to claim 28 wherein the membrane translocation sequence is the membrane translocation sequence of the *Drosophila melanogaster* antennapedia protein.

30. (new) A pharmaceutical composition comprising a polypeptide according to any one of claims 21 to 29 together with a pharmaceutically acceptable diluent or carrier.

31. (new) A pharmaceutical composition according to claim 30 which further comprises a cytostatic or cytotoxic agent.

32. (new) A composition formulation comprising a polypeptide of SEQ ID NO:1 in the form of an orally, topically, or parenterally administratable form.

33. (new) A method of inducing apoptosis in a cell which comprises introducing into said cell an effective amount of a polypeptide according to claim 21.

34. (new) A method according to claim 33 wherein said cell is a tumour cell.

35. (new) A method according to claim 33 wherein said cell is a cardiovascular cell.

36. (new) A product comprising a polypeptide consisting essentially of a sequence corresponding to residues 163 to 199 of DP-1, said sequence being:

KNIRRRVYDALNVLMAMNIISKEKKEIKWIGLPTNSA (SEQ ID NO:1),

and a cytostatic or cytotoxic agent as a combined preparation.

37. (new) A method of treating uncontrolled proliferation of cells in a human or animal body in need of said treating comprising administering a composition of claim 31 to said human or animal body such that said uncontrolled proliferation of cells is treated.